Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Ronald Walker, MD, John Shaughnessy, PhD, Jeffery Haessler, MS, Joshua Epstein, DSc, Jeffery Sawyer, PhD, Elias J. Anaissie, MD, Frits Van Rhee, MD PhD, Guido Tricot, MD PhD, Maurizio Zangari, MD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, John Crowley, MD, Bart Barlogie, MD PhD

Blood (2006) 108 (11): 3515.

https://doi.org/10.1182/blood.V108.11.3515.3515

Published: 2006

Journal Articles

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Varant Arzoumanian, MD, Bart Barlogie, MD,PhD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, Elias Anaissie, MD, Maurizio Zangari, MD, Somashekar Krishna, MD, Eilas Kiwan, MD, Guido Tricot, MD,PhD, Abid Mohiuddin, MD, Frits van Rhee, MD,PhD

Blood (2006) 108 (11): 3561.

https://doi.org/10.1182/blood.V108.11.3561.3561

Published: 2006

Journal Articles

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Choon-Kee Lee, MD, Annick E. Tricot, Athanasios Fassas, MD, Elias Anaissie, MD, Klaus Hollmig, MD, Raymond Thertulien, MD, Giampaolo Talamo, MD, Frits van Rhee, MD, PhD, Julie M. Stover, BA, Louis Fink, MD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4914.

https://doi.org/10.1182/blood.V104.11.4914.4914

Published: 2004

Journal Articles

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampaolo Talamo, MD, Athanasios Fassas, MD, Choon-Kee Lee, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2399.

https://doi.org/10.1182/blood.V104.11.2399.2399

Published: 2004

Journal Articles

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Maurizio Zangari, MD, Julie Stover, Lisa Jackson, Teresa Milner, Athanasios Fassas, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 538.

https://doi.org/10.1182/blood.V104.11.538.538

Published: 2004

Journal Articles

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Athanasios Fassas, MD, Erik Rasmussen, Raymond Thertulien, MD, PhD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 1480.

https://doi.org/10.1182/blood.V104.11.1480.1480

Published: 2004

Journal Articles

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampalamo Talamo, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Frits van Rhee, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 929.

https://doi.org/10.1182/blood.V104.11.929.929

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Guido Tricot, MD, PhD, John Crowley, PhD, Julie Stover, BA, Teresa Milner, BS, Athanasios Fassas, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Elias Anaissie, MD, Frits van Rhee, MD, PhD, Giampalamo Talamo, MD, Klaus Hollmig, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 936.

https://doi.org/10.1182/blood.V104.11.936.936

Published: 2004

Journal Articles

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Blood (2004) 104 (11): 784.

https://doi.org/10.1182/blood.V104.11.784.784

Published: 2004

NARROW

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only